Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080210
Status:
COMPLETED
Last Update Posted:
2013-06-03
First Post:
2004-03-24
Brief Title:
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
Sponsor:
Savient Pharmaceuticals
Organization:
Savient Pharmaceuticals
Study Overview
Official Title:
A Phase II Study of Multiple Doses of Intravenous Puricase in Subjects With Hyperuricemia and Refractory Gout
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized open-label multicenter parallel-groups study of multiple intravenous doses of Puricase administered intravenously in 40 patients with symptomatic gout Subjects must wash out of any uric acid-lowering agents for one week before being dosed and must refrain from using such agents throughout the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None